• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Axsome Therapeutics Inc.

    4/25/25 4:32:39 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    DEFA14A 1 axsm_2025_april_proxy_-_.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.)

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    AXSOME THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

    img242522476_0.jpg

     

    Logo axsome therapeutics, inc. One world trade center, 29th floor new york, ny 10007 your vote counts! Axsome therapeutics, inc. 2025 annual meeting vote by june 5, 2025 11:59 pm et v69578-p30802 you invested in axsome therapeutics, inc. And it’s time to vote! You have the right to vote on proposals being presented at the annual meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on june 6, 2025. Get informed before you vote view the notice, proxy statement and annual report online or you can receive a free paper or email copy of the material(s) by requesting prior to may 23, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.proxyvote.com control # smartphone users point your camera here and vote without entering a control number vote virtually at the meeting* june 6, 2025 9:00 am edt virtually at: www.virtualshareholdermeeting.com/axsm2025 *please check the meeting materials for any special requirements for meeting attendance.


     

    img242522476_1.jpg

     

    Vote at www.proxyvote.com this is not a votable ballot this is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting items board recommends 1. Election of director nominee: 01) roger jeffs, ph.d. 2. To approve the company’s 2025 long-term incentive plan. 3. To ratify the appointment of deloitte & touche llp as the company’s independent registered public accounting firm for the year ending december 31, 2025. 4. To approve, by non-binding advisory vote, the compensation of our named executive officers. Note: such other business as may properly come before the meeting or any adjournment thereof. For for for for Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V69579-P30802


    Get the next $AXSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    4/29/2024$90.00 → $115.00Equal-Weight → Overweight
    Morgan Stanley
    3/19/2024$108.00Outperform
    Robert W. Baird
    More analyst ratings

    $AXSM
    SEC Filings

    See more
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/27/25 7:05:49 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Axsome Therapeutics Inc.

      SCHEDULE 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      5/15/25 8:09:32 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/13/25 7:06:16 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics to Participate in Upcoming Investor Conferences

      NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June: William Blair 45th Annual Growth Stock ConferenceThe Company will present on Tuesday, June 3, 2025, at 10:40 a.m. CT in Chicago, IL Jefferies Global Healthcare ConferenceThe Company will present on Thursday, June 5, 2025, at 2:35 p.m. ET in New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceThe Company will present on Monday, June 9, 2025, at 2:40 p.m. ET in Miami Beach, FL Live webcasts of the p

      5/29/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

      NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations from three of its innovative neuroscience programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting, being held from May 27-30 in Scottsdale, Arizona. Details of the presentations are as follows: AUVELITY Title: Initiating Dextromethorphan 45 mg - Bupropion 105 mg (AUVELITY®) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus RecommendationsLead Author: Anita Clayton, MD, Wilford W. Spradlin Professor and Chair of Ps

      5/28/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

      NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. U

      5/27/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 3:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 7:26:39 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/13/24 4:58:57 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      11/28/23 6:51:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

      NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

      10/11/23 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Coleman Mark sold $783,375 worth of shares (7,500 units at $104.45), decreasing direct ownership by 14% to 46,637 units (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      5/29/25 7:00:05 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Jacobson Mark L. exercised 40,673 shares at a strike of $6.47 and sold $4,232,636 worth of shares (40,673 units at $104.07) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      5/28/25 9:52:55 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coleman Mark sold $322,473 worth of shares (3,000 units at $107.49), decreasing direct ownership by 5% to 54,137 units (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      5/20/25 9:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Financials

    Live finance-specific insights

    See more
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity® 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth Sunosi® 4Q and full year 2024 net product revenue of $26.2 million and $94.3 million, respectively, representing 16% and 26% year-over-year growth Symbravo® approved in the U.S. for the acute treatment of migraine with or without aura in adults Successful completion of Phase 3 clinical program of AXS-05 in Alzh

      2/18/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

      Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      8/19/22 12:36:14 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Axsome Therapeutics with a new price target

      Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

      4/7/25 8:43:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Axsome Therapeutics with a new price target

      Deutsche Bank initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $176.00

      2/11/25 7:01:14 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho reiterated coverage on Axsome Therapeutics with a new price target

      Mizuho reiterated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $122.00 from $124.00 previously

      12/31/24 7:54:59 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care